Copd News

Main Category: Respiratory / Asthma Also Included In: Medical Devices / Diagnostics In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors were used to show that nebulized formoterol fumarate improves pulmonary function.

Sosei Group Corporation and Vectura Group plc announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease .

We have heard about the many benefits of the Mediterranean Diet. Food prepared with Mediterranean diet recipes have shown to to improve heart health , stroke, longevity*, diabetes and now helping COPD according to a Thorax study.

WALTHAM, Mass. , June 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a 28 percent increase in the diagnosed prevalent population will drive growth in the chronic obstructive pulmonary disease drug market in , France , Germany , Italy , Spain , the ...

Wednesday, June 17, 2009 at 10:22 a.m. Provided by A If you are young and you smoke, here's another reason to quit.

Liz Dawn talks about becoming an ambassador for the British Lung Foundation and living with COPD.

I have chronic obstructive pulmonary disease . A year ago, I was given a parrot.

The changes that COPD brings may magnify or change existing family roles, making life with loved ones less predictable for a while.

Chronic Obstructive Pulmonary Disease, or COPD is the fourth leading cause of death in the United States.

Pulmonary rehabilitation is known to be a beneficial treatment for COPD patients.

Main Category: COPD Also Included In: Respiratory / Asthma Article Date: 27 May 2009 - 5:00 PDT Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease show that budesonide/formoterol plus tiotropium significantly improves disease control and patients' quality of life.1,2 ...

The Novartis investigational bronchodilator QAB149 met the primary efficacy endpoints of improved lung function compared to placebo at 12 weeks in three pivotal phase III studies in chronic obstructive pulmonary disease patients.

Data presented at this year's American Thoracic Society congress, demonstrated that SYMBICORT added to SpirivaTM provided greater clinical improvements than tiotropium alone over a 12-week treatment period.1,2 Results of the CLIMB study showed that the occurrence of severe exacerbations was reduced by as much as 62 percent in patients where ...

San Diego, Data presented at this yeara s American Thoracic Society congress, demonstrated that SYMBICORTA added to SpirivaTM provided greater clinical improvements than tiotropium alone over a 12-week treatment period.1,2 Results of the CLIMB study showed that the occurrence of severe exacerbations was reduced by as much as 62 percent in patients ...

Novartis ' investors can breathe a little easier. The company's new treatment for chronic obstructive pulmonary disease -- a.k.a. "smoker's lung" -- passed its three phase 3 trials without so much as a cough.

BASEL,A Switzerland Early results of a phase 3 trial have shown that an investigational treatment for chronic obstructive pulmonary disease can improve lung function within five minutes of the first dose.

Basel, - Initial results from three pivotal phase III trials show the Novartis investigational bronchodilator QAB149 could deliver clinically relevant[1][1] lung function improvements, within five minutes of the first dose, lasting for 24 hours in patients with chronic obstructive pulmonary disease 3,4,5. The data presented at the American Thoracic ...

A lifestyle intervention program that promoted exercise, healthy eating and quitting smoking improved the health of people with mild to moderate chronic obstructive pulmonary disease and was cost-effective, a new study shows.

Posted 01:00 AM ET KENILWORTH, N.J., May 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease .

The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Novartis assumes exclusive worldwide development and marketing rights for investigational once-daily QMF149 being developed for COPD and asthma * QMF149 combines QAB149 with mometasone and is ...